Latest News
The article compares Ethereum with legacy payment and settlement rails, covering ECB Pontes, tokenized finance, bank tests, and DTCC's tokenization push.
Via Visibility · October 14, 2026
Institutional funds, ETFs, staking rewards and futures are reshaping Ether’s dollar price. The article explains how professional capital changes market behavior.
Via Visibility · October 13, 2026
As goeasy’s management is working to stabilize the business and improve its credit performance, its dividend could remain suspended.
Via The Motley Fool · October 14, 2026
VanEck's uranium fund yields 3.1% but lost 28% last year, while iShares' renewable portfolio gained 8.3% with lower costs.
Via The Motley Fool · October 14, 2026
Solana's new deal with Samsung is another piece of evidence that it's worth owning.
Via The Motley Fool · October 14, 2026
This Canadian stock yields about 5.8% and has a solid dividend growth history backed by a resilient business model and growing cash flow.
Via The Motley Fool · October 14, 2026
It hasn't always been easy, but the Vanguard S&P 500 ETF is pacing ahead of where it was during the first 20 months of President Trump's first term in office.
Via The Motley Fool · October 14, 2026
Camtek (NASDAQ:CAMT) outlined a higher long-term revenue target at its investor and analyst breakfast held alongside SEMICON West, citing demand for advanced semiconductor packaging equipment tied to artificial intelligence applications.
Chief Executive Officer Rafi Amit said the company expects th
Via MarketBeat · October 14, 2026
Dollarama stock continues to benefit from positive momentum in its retail operations in all countries that it operates.
Via The Motley Fool · October 14, 2026
The company's board of directors can play a vital role in positioning the company to develop the next generation of aircraft.
Via The Motley Fool · October 14, 2026
Here’s why this monthly dividend stock could be an ideal addition to your TFSA if you’re looking for retirement income and long-term growth.
Via The Motley Fool · October 14, 2026
September inflation could change mortgage offers before the Bank of Canada acts. Here’s how to prepare without predicting the report.
Via The Motley Fool · October 14, 2026
With an expanding 18% free cash flow margin and massive share buybacks, Shopify proves why it remains a top TSX stock to hold long term.
Via The Motley Fool · October 14, 2026
TELUS cut its dividend by 55%, yet shares yield 7.4%. See what the dividend reset means for income investors and whether the stock is a buy now.
Via The Motley Fool · October 14, 2026
Small-cap stocks might be ready to deliver big-time gains for long-term investors.
Via The Motley Fool · October 14, 2026
Use Canada’s registered accounts to save and invest to help realize your early-retirement dream!
Via The Motley Fool · October 14, 2026
A small rate surprise matters less when you already have written offers, payment calculations, and clear contract terms.
Via The Motley Fool · October 14, 2026
Two of the seven down years erased over half the stock's value. What went wrong?
Via The Motley Fool · October 14, 2026
NioCorp Developments (NASDAQ:NB) hosted federal and state officials at its Elk Creek Critical Minerals Mine and Processing Facility site in Nebraska, where company leaders and policymakers emphasized the project’s potential role in building domestic supplies of minerals used in defense, aerospace, m
Via MarketBeat · October 14, 2026
These Canadian stocks can help build a balanced portfolio that offers long-term growth while generating income through dividends.
Via The Motley Fool · October 14, 2026
Given its established business model, predictable rental income, consistent distributions, and visible growth opportunities, CT REIT could be a compelling option for retirees.
Via The Motley Fool · October 14, 2026
Two simple rules also keep Berkshire Hathaway, Visa, and Oracle out of the popular fund.
Via The Motley Fool · October 14, 2026
Google Cloud's growth will justify its major spending.
Via The Motley Fool · October 14, 2026
While Tesla may have intended for its China production to stay in China, a brutal price war and increasing competition have forced a new strategy.
Via The Motley Fool · October 14, 2026
Arrowhead Pharmaceuticals (NASDAQ:ARWR) presented interim Phase I/II data for ARO-MAPT, an investigational small interfering RNA therapy designed to reduce tau protein expression in the central nervous system, alongside initial clinical results for its TRiM CNS delivery platform.
The company said t
Via MarketBeat · October 14, 2026